Gliomas are the most common central nervous system tumors. They show malignant characteristics indicating rapid proliferation and a high invasive capacity and are associated with a poor prognosis. In our previous study, p68 was overexpressed in glioma cells and correlated with both the degree of glioma differentiation and poor overall survival. Downregulating p68 significantly suppressed proliferation in glioma cells. Moreover, we found that the p68 gene promoted glioma cell growth by activating the nuclear factor-κB signaling pathway by a downstream molecular mechanism that remains incompletely understood. In this study, we found that dual specificity phosphatase 5 (DUSP5) is a downstream target of p68, using microarray analysis, and that p68 negatively regulates DUSP5. Upregulating DUSP5 in stably expressing cell lines (U87 and LN-229) suppressed proliferation, invasion, and migration in glioma cells in vitro, consistent with the downregulation of p68. Furthermore, upregulating DUSP5 inhibited ERK phosphorylation, whereas downregulating DUSP5 rescued the level of ERK phosphorylation, indicating that DUSP5 might negatively regulate ERK signaling. Additionally, we show that DUSP5 levels were lower in high-grade glioma than in low-grade glioma. These results suggest that the p68-induced negative regulation of DUSP5 promoted invasion by glioma cells and mediated the activation of the ERK signaling pathway.
K E Y W O R D S
DUSP5, glioma, invasion, migration, p68/DDX5 surrounding normal brain tissue remain unclear. 2, 3 Therefore, increasing our understanding of the molecular mechanisms underlying the invasive behavior of glioma is essential for developing novel therapeutic approaches to treat aggressive glioma invasiveness.
P68 (also known as DDX5) is considered a member of the prototypic DEAD-box family of RNA helicases. 4, 5 Because it is an ATPdependent RNA helicase, p68 can manipulate RNA structures, including pre-mRNA, rRNA, and microRNA. [6] [7] [8] [9] [10] [11] P68 could also act as a transcriptional coactivator of several cancer-associated transcription factors, such as p53 tumor suppressor, 11 β-catenin, 12 and the androgen receptor, 13 which plays an essential role in cell proliferation, oncogenesis, and early stage organ development.
14 Indeed, p68 is aberrantly expressed or modified in different types of tumors, including breast, prostate, and colon cancer. 13, 15, 16 Our previous results showed that p68 protein levels were significantly higher in high-grade glioma and that a high expression level of p68
was associated with poor survival in glioma patients. Moreover, we found that p68 induced glioma tumor growth by binding to nuclear factor-κB (NF-κB) p50, indicating that p68 plays a significant role in gliomagenesis. 17 However, the downstream molecular mechanism by which p68 regulates the invasive behavior of glioma remains unclear.
In mammalian cells, dual specificity phosphatases (DUSPs, also known as mitogen-activated protein kinase phosphatases) include 16 catalytically active enzymatic family members. Dual specificity phosphatase 5 (DUSP5) is a growth factor-inducible phosphatase that possesses a functional nuclear localization signal that targets and anchors ERK1 and ERK2 to the nucleus. 18, 19 It plays an essential role in cellular proliferation and differentiation by negatively regulating members of the MAPK superfamily (MAPK/ERK, SAPK/JNK, and p38). 20 Because DUSP5 performs such comprehensive functions, studies aimed at exploring the role of DUSP5 in glioma are of great interest.
Here, we use a microarray gene expression analysis to reveal that the DUSP5 gene acts as a downstream target of p68. Both p68 knockdown and DUSP5 upregulation suppressed proliferation, invasion, and migration in glioma cells in vitro. Moreover, we found that upregulating DUSP5 impaired p68-induced glioma proliferation, invasion, and migration. In addition, we found that DUSP5 could negatively regulate ERK phosphorylation, indicating the potential existence of a p68/DUSP5/ERK signaling-mediated mechanism in glioma. These results suggest that p68 induces invasiveness in glioma cells by negatively regulating DUSP5 and that DUSP5 acts as a negative regulator of glioma cell motility and the ERK pathway. 
| MATERIAL S AND ME THODS

| Cell line, cell culture, and cell transfection
| Clinical samples and histology
| Quantitative real-time PCR
| Gene expression profiling
The mRNA expression levels of genes of interest were analyzed in U87 glioma cells after p68 knockdown in a Human Twin Chip Human 44 K (Genocheck, Ansan, Korea) microarray analysis. Total cell RNA was isolated using TRIzol reagent after cells were transfected with p68 siRNA or an siRNA negative control (si-NC). Gene expression was normalized and differential expression analyzed using GeneSpring GX 7.3 (Agilent Technology, Folsom, CA, USA). All microarray data have been submitted to the Gene Expression Omnibus database (GEO accession no. GSE103981). 
| Western blot analysis
| Immunofluorescence
Transfected cells were fixed in 4% paraformaldehyde, permeabi- and mounted with mounting medium containing DAPI in preparation for fluorescence. Images were captured using Biorevo BZ-9000 fluorescence microscopy (Keyence, Osaka, Japan) and inverted LSM510 confocal laser microscopy (Carl Zeiss, Oberkochen,
Germany). 
| Immunohistochemical staining
| Cell proliferation assay
In the MTT assays, transfected cells were seeded in 96-well plates at a density of 2000 cells/well, cultured at 37°C in 5% CO 2 for 48 hours, treated with 20 μL MTT at 37°C for 4 hours, stopped with 100 mL DMSO, and analyzed at 570 nm by a multiwell plate reader.
| Wound-healing assay
Transfected cells were seeded in 6-well plates (1 × 10 5 cells/ well), washed with serum-free medium, and then incubated with serum-free DMEM at 37°C for 8 hours. Each sample was captured, and relative cell mobility was calculated by the following formula: relative mobility = (1 − distance between the edges of invaded scratches/distance between the edges of initial scratches) × 100%. 
| Transwell assay
| Statistical analysis
Statistical comparisons of the results obtained between 2 different groups were analyzed by Student's t test using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). The data are presented as the mean ± SD, and P < .05 was considered statistically significant.
| RE SULTS
| Expression of p68 in glioma cell lines and tissues
The mRNA expression level of p68 was significantly different among these 6 glioma cell lines. P68 was expressed at higher levels in LN-229 and U87 cells than in U251, A172, Hs683, and OL cells ( Figure 1A ). An approximately 68-kDa single band representing p68 was clearly detected in all cell lines but was most strongly detected in LN-229 and U87 glioma cells ( Figure 1B) , consistent with the qRT-PCR analysis. To assess the efficiency of the p68 siRNA for knocking down p68 in glioma cell lines, we selected the LN-229 and U87 cell lines because they expressed the highest levels of p68.
In immunohistochemistry specimens obtained in diffuse astrocytoma and GBM, p68 was predominantly immunolocalized in cell nuclei in malignant GBM, whereas only faint staining was detected in neoplastic astrocytes in diffuse astrocytoma ( Figure 1C ). The density of p68-positive cells was significantly higher in GBM than in diffuse astrocytoma when random microscopic fields were analyzed at the same magnification ( Figure 1C , left panels).
| DUSP5 acts downstream of p68
To gain a global view of the signaling pathways engaged by the p68 gene in glioma cell lines, we undertook a microarray analysis to verify the gene profiling results obtained after p68 silencing (Figure 2 ).
Whole-genome expression profiling of U87 cells transfected with p68 siRNA revealed that DUSP5 was expressed at 2-fold or higher levels in U87 cells transfected with p68 siRNA than in those transfected with an si-NC, suggesting that DUSP5 acts downstream of p68 ( Figure 2D ).
To further verify this result, we downregulated the p68 gene in both U87 and LN-229 cells and found that the DUSP5 mRNA was expressed at high levels in both U87 and LN-229 cells following treatment with p68 siRNA ( Figure 3A ) and that DUSP5 protein levels were higher in cells transfected with the p68 siRNA than in cells transfected with the siRNA control and si-NC groups ( Figure 3B ). As expected, immunofluorescence analysis showed that immunofluorescent staining for DUSP5 was increased after p68 was silenced and that p68 colocalized with DUSP5 at the subcellular level ( Figure 3C ). To evaluate the expression of the C, Immunolocalization of p68 in diffuse astrocytoma (DA; upper panels) and glioblastoma (GBM; lower panels) tissues. Note that p68 immunolocalizes to neoplastic astrocytes (right panels, arrowheads). Strong staining was detected in GBM tissues (lower panels), whereas faint staining was observed in DA tissues (upper panels) F I G U R E 3 Expression of dual specificity phosphatase 5 (DUSP5) in glioma cells after p68 knockdown and immunolocalization of DUSP in diffuse astrocytoma and glioblastoma. A, DUSP5 mRNA expression after p68 knockdown. B, Histogram of relative p68 or DUSP5 protein expression levels with relative ratios shown as percentages of the p68/GAPDH or DUSP5/GAPDH band. C, Immunofluorescence assay of the cellular localization of p68 and DUSP5. Scale bar = 50 μm. D, Immunohistochemical staining for DUSP5 shows its protein levels in diffuse astrocytoma (DA, upper panels) and glioblastoma (GBM, lower panels) tissues and 46.78 ± 2.68, respectively; P < .05) compared to the results obtained in the control and si-NC groups (1.00 ± 0.02 and 1.01 ± 0.08, respectively), whereas there was no detectable effect in the control and negative transfection groups (100.00 ± 4.64 and 95.32 ± 3.65, respectively; Figure 4B ,C). These results indicate that p68 knockdown suppressed proliferation, invasion and migration in glioma cells in vitro.
| DUSP5 suppresses proliferation, invasiveness, and migration in glioma cells
We next investigated whether DUSP5 overexpression regulates cell proliferation, migration, and invasion in U87 and LN-229 cells transfected with DUSP5 plasmids, both of which showed relatively lower expression levels of DUSP5 ( Figure 3B ). These high mRNA and protein levels of DUSP5 were validated by qRT-PCR and immunoblotting, whereas transfection with a control plasmid vector or an empty plasmid vector had no effect on DUSP mRNA and protein levels ( Figure 5A ,B). To further evaluate the subcellular localization of DUSP5, we undertook an immunofluorescence analysis of U87 and LN-229 cells transfected with DUSP5.
Immunofluorescence staining results showed that, in these cells, DUSP5 was expressed at higher levels and mainly localized in the nuclear membrane and cytoplasm compared to the results observed in the control plasmid vector-or empty plasmid vectortreated groups ( Figure 5C ). The cytological localization of DUSP5
was consistent with the membrane-anchored behavior associated with a nuclear protein.
In cell proliferation assays, proliferation was significantly lower in DUSP5-overexpressing U87 and LN-229 cells (mean ± SD, 0.63 ± 0.003 and 0.64 ± 0.02, respectively; P < .05) than in the control groups (0.97 ± 0.01 and 0.96 ± 0.01, respectively; and 0.97 ± 0.005 and 0.95 ± 0.004; respectively, Figure 5D ). The effects of DUSP upregulation on cell invasion were next tested, and the results showed that the rate of cell invasion in monolayer cell surfaces was also significantly lower in U87 and LN-229 cells transfected with a DUSP plasmid (1.96 ± 0.05 and 1.60 ± 0.05, respectively; P < .05) than in control-transfected cells (1.00 ± 0.03 and 1.03 ± 0.04, respectively and; 1.00 ± 0.02 and 1.03 ± 0.06, respectively; Figure 5E ). Similarly, migration assays indicated that the rate of migration was significantly lower in U87 and LN-229 cells in which DUSP was upregulated (41.06 ± 3.04 and 52.00 ± 2.36, respectively; P < .05) than in those transfected with the control vector (100.00 ± 4.13 and 97.35 ± 3.97, respectively; and 100.00 ± 5.94 and 94.49 ± 2.36, respectively; Figure 5F ). A normal DUSP5-activated level of glioma cell motility was rescued in glioma cells cotransfected with both a DUSP5 vector and DUSP5 siRNA but not in those treated with the DUSP5 vector alone. These data confirmed that DUSP5 suppresses proliferation, invasion, and migration in U87 and LN-229 cells and suggest that DUSP5 affects glioma chemotactic behavior in vitro.
| DUSP5 impairs p68-induced proliferation, invasion, and migration and negatively regulates ERK signaling
To gain further insight into the potential role of the DUSP5 gene in the malignant behavior of human gliomas, we undertook proliferation, invasion, and migration assays in cells transfected with p68 siRNA and/or DUSP5 siRNA. The mRNA and protein levels of DUSP5 were assessed by qRT-PCR and immunostaining in cells cotransfected with p68 siRNA and DUSP5 siRNA ( Figure 6A,B) . A chemotactic functional analysis revealed that, in U87 and LN-229 cells, DUSP5 knockdown resulted in a higher rate of cell motility than was observed in the control-transfected cells ( Figure 5 ).
Cotransfection with p68 siRNA and DUSP5 siRNA (mean ± SD, 0.83 ± 0.008 and 0.88 ± 0.005, respectively; P < .05; Figure 6C) rescued the proliferation-inhibiting effect of p68 siRNA in U87 and LN-229 cells, suggesting that DUSP5 acts in part by impairing p68-induced proliferation in glioma cells.
Similar findings were observed in an invasion and migration assay. As shown in Figure 6D , the rate of scratch-stimulated cell invasion on the bottom of the well was higher in U87 and LN-229 cells treated with p68 siRNA (1.87 ± 0.06 and 1.93 ± 0.14, respectively; P < .05) than in control-transfected cells (1.00 ± 0.02 and 1.01 ± 0.08, respectively; Figure 6D ), whereas U87 and LN-229 cells cotransfected with p68 siRNA and DUSP5 siRNA had lower rates of invasion (1.20 ± 0.09 and 1.17 ± 0.11, respectively; P < .05). We found a similar result in migration assays carried out in cells cotransfected with p68 siRNA and DUSP5 siRNA ( Figure 6E ). Collectively, these functional assays indicate that DUSP5 impairs p68-induced motility in glioma cells.
In these experiments, we attempted to identify which downstream signaling pathway is involved in the regulation of DUSP5.
As shown in Figure S1 
| D ISCUSS I ON
Gliomas are the most common type of primary brain tumors in adults, in which they account for approximately 80% of all malignant CNS tumors and are associated with substantial morbidity and mortality. 22 Gliomas are classified into WHO grades I-IV according to differences in morphological characteristics, with a higher grade usually indicating a poorer prognosis. 23, 24 Glioblastomas (WHO grade IV) are the most malignant tumors in the spectrum of diffuse astrocytomas; they have the highest recurrence rate and the worst prognosis, in addition to a high risk of radioresistance and chemoresistance. 25 Thus, it is important to investigate the detailed mechanisms underlying growth and invasion in gliomas. In our study, we
show that p68 is highly expressed in both glioma cells and tissues and these results indicate that p68 negatively regulates DUSP5 to promote proliferation, invasion, and migration in glioma cells. Our previous study showed that p68 combined with nuclear factor-κB p50 to promote glioma proliferation. These studies emphasize the notion that p68 plays a chemotactic role in gliomagenesis, and we predict a novel therapeutic target, DUSP5, for glioma therapy.
17
P68 is an oncogene that is overexpressed in colorectal tumors, 15 in which downregulating p68 reduced proliferation and tumor formation in nude mice. 26 P68 is overexpressed in prostate tumors, in which it promotes prostate tumorigenesis, 13 and it is overexpressed in breast tumors, in which it regulates target gene transcription and promotes tumorigenesis. 16 Our results verify that p68 is overexpressed in glioma tumors, and we show that p68 knockdown inhibited growth and invasiveness in glioma, suggesting that p68 plays an important role in glioma therapy. Additional analyses of the functions of the downstream signaling pathways of p68 in glioma will be required to further address this question. In our study, we show that a novel gene, DUSP5, functions downstream of p68 and interacts with p68 to regulate glioma growth. DUSP5 interacts specifically with p68; however, the exact binding site at which DUSP5 binds p68 was not identified. The DUSP family comprises a group of tyrosine or serine/threonine phosphatases that are involved in cancer progression and resistance and could be regarded as a novel rational target. 27 As a vital member of the DUSP family, DUSP5 localizes solely in cellular nuclei, 28 possesses a functional nuclear localization signal, and has been proposed to act as a nuclear anchor for ERK. 19 As a growth factor-inducible phosphatase, DUSP5 is critical for both vascular development and disease. 29 Previous studies showed that DUSP5 is a novel prognostic biomarker for advanced colorectal cancer patients 30 and that it can prevent progression in prostate cancer patients. 31 However, the precise role of DUSP5 in glioma remains unclear. The results of our study show that DUSP5 expression is associated with glioma differentiation and that DUSP5 expression was lower in high-grade gliomas. Here, our findings also indicate that DUSP5 might act as a tumor suppressor during progression in glioma. To our knowledge, our study is the first to explore the molecular functions and roles underlying the clinicopathological effects of DUSP5 in glioma.
In this study, we reveal that DUSP5 functions as a tumor suppressor and inhibits tumor growth. As a member of the dualspecificity phosphatase family that specifically inactivates ERK,
32
DUSP5 is a component in one of three branches of the MAPK cascade that function in tumors. Abnormal MAPK signaling is closely related to the development and progression of tumors. 32 Moreover, increasing evidence indicates that DUSP5 plays a key role in inhibiting tumor proliferation and growth. 31 A recent study showed that DUSP5 suppressed skin cancer by regulating nuclear ERK activation. 33 In gastric cancer, DUSP5 inhibited tumor cell growth and colony-forming ability by regulating the cell cycle transition from effects of a serine threonine kinase, Snrk-1. In our study, we found that DUSP5 negatively regulated ERK expression and phosphorylation, indicating a novel molecular mechanism involving p68/ DUSP5/ERK in glioma. In summary, p68/DUSP5 might participate in various functions during tumorigenesis by negatively targeting ERK signaling, which facilitates glial tumorigenesis. However, the underlying molecular mechanism by which it exerts these effects needs to be further explored.
Finally, the results of our study reveal that p68 might exert inhibitory effects on the regulation of chemotactic cell invasion and migration by negatively regulating DUSP5/ERK signaling.
Improving our understanding of the mechanisms by which p68
negatively regulates DUSP5 will expand our knowledge of the molecular pathogenesis of glioma. Furthermore, the discoveries presented here represent a new facet of the complex interactions of the p68 gene and its tumor-promoting functions and provide novel insights into the potential roles of a p68/DUSP5/ERK signaling pathway in carcinogenesis.
